EMA Authorised: Forsteo (teriparatide) — Eli Lilly Nederland B.V.

View source ↗

Summary

The European Medicines Agency authorised Forsteo (teriparatide) for osteoporosis, including postmenopausal osteoporosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoporosis
• Postmenopausal Osteoporosis

Drugs mentioned

• Forsteo® (teriparatide)

Snippet

Status: Authorised. Therapeutic area: Osteoporosis;Osteoporosis, Postmenopausal. MAH: Eli Lilly Nederland B.V.. Decision date: 27/01/2026